Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis

Yee-Suk Kim, Yuxi Tian, Jianxiao Yang, Vojtech Huser, Peng Jin, Christophe G Lambert, Hojun Park, Seng Chan You, Rae Woong Park, Peter R. Rijnbeek, Mui Van Zandt, Christian Reich, Rohit Vashisht, Yonghui Wu, Jon Duke, George Hripcsak, David Madigan, Nigam H. Shah, Patrick Ryan, Martijn J. Schuemie, Marc A. SuchardScientific 2020 · DOI

Abstract

This large-scale multicenter study compared the effectiveness and safety of alendronate and raloxifene in over 300 million patients across nine international databases. The primary outcome was the incidence of osteoporotic hip fracture. Results indicated that both treatments provide similar protection against hip fractures (HR 1.03, 95% CI 0.94-1.13). However, alendronate was associated with a significantly higher risk of atypical femoral fractures (HR 1.51) and a slightly higher risk of vertebral fractures (HR 1.07). These findings suggest that raloxifene is a competitive and potentially safer first-line treatment option for osteoporosis.

Introduction

Osteoporosis represents a significant global health challenge, particularly for postmenopausal women. While alendronate, a bisphosphonate, and raloxifene, a selective estrogen receptor modulator (SERM), are both widely prescribed, direct head-to-head comparative evidence has been lacking. Clinical guidelines often favor alendronate based on placebo-controlled trials, yet bisphosphonates are linked to rare but serious adverse events like atypical femoral fractures (AFF). This study sought to provide high-quality real-world evidence to guide clinical decision-making by leveraging a massive federated data network.

Methodology: Large-Scale Observational Research

The researchers utilized a retrospective, new-user cohort design within the Observational Health Data Sciences and Informatics (OHDSI) framework. By employing the OMOP Common Data Model (CDM), the study standardized data across nine diverse healthcare databases, including electronic health records and insurance claims from the US and South Korea, encompassing over 300 million patients.

To minimize bias, the study used:

  • Expansive Propensity Score (PS) Modeling: Incorporating all available pre-treatment patient characteristics to account for confounding by indication.
  • Negative Control Calibration: Testing the model against 147 unrelated outcomes to adjust for systematic bias and produce robust calibrated p-values.

Key Results: Effectiveness and Safety

The final cohort included 283,586 alendronate patients and 40,463 raloxifene patients.

Primary Outcome: Hip Fracture

The study found no significant difference in the risk of hip fractures between the two cohorts. The summary hazard ratio was 1.03 (95% CI 0.94–1.13), demonstrating parity in primary protection across various database types.

Forest plot of hazard ratios for hip fracture across nine databases in primary and alternative analyses.

Secondary Outcomes and Safety

  • Atypical Femoral Fracture (AFF): Alendronate users faced a 51% higher risk of AFF (HR 1.51, 95% CI 1.23–1.84).
  • Vertebral Fracture: Surprisingly, alendronate was associated with a slightly higher risk of vertebral fractures compared to raloxifene (HR 1.07, 95% CI 1.01–1.14).
  • Other Safety Concerns: No statistically significant differences were observed for esophageal cancer (HR 0.95) or osteonecrosis of the jaw (ONJ, HR 1.62).

Discussion and Clinical Implications

This study challenges the prevailing preference for alendronate by demonstrating that raloxifene is equally effective at preventing hip fractures while potentially carrying a lower risk of atypical femoral fractures. While limitations exist—such as the lack of Bone Mineral Density (BMD) data and potential channeling bias regarding thromboembolism—the methodological rigor and scale of this research provide strong evidence for raloxifene as a robust alternative in osteoporosis management. Future research should investigate the long-term effects of treatment duration and the impact of "drug holidays" on these comparative outcomes.

Summary updated

Abstract

Alendronate and raloxifene are among the most popular anti-osteoporosis medications. However, there is a lack of head-to-head comparative effectiveness studies comparing the two treatments. We conducted a retrospective large-scale multicenter study encompassing over 300 million patients across nine databases encoded in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The primary outcome was the incidence of osteoporotic hip fracture, while secondary outcomes were vertebral fracture, atypical femoral fracture (AFF), osteonecrosis of the jaw (ONJ), and esophageal cancer. We used propensity score trimming and stratification based on an expansive propensity score model with all pre-treatment patient characteritistcs. We accounted for unmeasured confounding using negative control outcomes to estimate and adjust for residual systematic bias in each data source. We identified 283,586 alendronate patients and 40,463 raloxifene patients. There were 7.48 hip fracture, 8.18 vertebral fracture, 1.14 AFF, 0.21 esophageal cancer and 0.09 ONJ events per 1,000 person-years in the alendronate cohort and 6.62, 7.36, 0.69, 0.22 and 0.06 events per 1,000 person-years, respectively, in the raloxifene cohort. Alendronate and raloxifene have a similar hip fracture risk (hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.94-1.13), but alendronate users are more likely to have vertebral fractures (HR 1.07, 95% CI 1.01-1.14). Alendronate has higher risk for AFF (HR 1.51, 95% CI 1.23-1.84) but similar risk for esophageal cancer (HR 0.95, 95% CI 0.53-1.70), and ONJ (HR 1.62, 95% CI 0.78-3.34). We demonstrated substantial control of measured confounding by propensity score adjustment, and minimal residual systematic bias through negative control experiments, lending credibility to our effect estimates. Raloxifene is as effective as alendronate and may remain an option in the prevention of osteoporotic fracture.
BibTeX
@inproceedings{kim2020comparative,
  author = {Yee-Suk Kim and Yuxi Tian and Jianxiao Yang and Vojtech Huser and Peng Jin and Christophe G Lambert and Hojun Park and Seng Chan You and Rae Woong Park and Peter R. Rijnbeek and Mui Van Zandt and Christian Reich and Rohit Vashisht and Yonghui Wu and Jon Duke and George Hripcsak and David Madigan and Nigam H. Shah and Patrick Ryan and Martijn J. Schuemie and Marc A. Suchard},
  title = {{Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-020-68037-8},
}
Figure